Tern extends Device Authority convertible loan note maturity date

Money and Investment

Tern Plc (LON:TERN), the investment company specialising in the Internet of Things, has announced that the maturity date for all convertible loan notes provided to Device Authority Limited by Tern, Alsop Louie Partners and the George Samenuk Family Trust et al., has been extended to 31 March 2022.  

All existing repayment and conversion rights, automatic and at the holder’s option, have also been extended to 31 March 2022.  All other terms of these loan notes remain unchanged and as previously announced.

The outstanding convertible loan balance payable by Device Authority to Tern currently stands at US$4.3 million, excluding US$0.6 million of interest accrued to date.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

A new frontier for medical device trust and patient safety

Connected medical device risk is rising and a platform that automates identity, credential and data‑protection lifecycles may become an infrastructure segment worth watching.

When HCP Dialogue Becomes Quantifiable Intelligence

Talking Medicines’ DrugVoice platform turns real‑world HCP dialogue into measurable insight, letting brand‑teams forecast message resonance before launch.

Search

Search